Literature DB >> 32066880

MAOA-mediated reprogramming of stromal fibroblasts promotes prostate tumorigenesis and cancer stemness.

Jingjing Li1,2, Tianjie Pu1,3, Lijuan Yin3,4, Qinlong Li5, Chun-Peng Liao6, Boyang Jason Wu7.   

Abstract

The tumor microenvironment plays a critical role in prostate cancer (PC) development and progression. Inappropriate activation of the stroma potentiates the growth and transformation of epithelial tumor cells. Here, we show that upregulation of monoamine oxidase A (MAOA), a mitochondrial enzyme that degrades monoamine neurotransmitters and dietary amines, in stromal cells elevates production of reactive oxygen species, triggers an inflammatory response including activation of IL-6, and promotes tumorigenesis in vitro and in vivo. Mechanistically, MAOA enhances IL-6 transcription through direct Twist1 binding to a conserved E-box element at the IL-6 promoter. MAOA in stromal fibroblasts provides tumor cell growth advantages through paracrine IL-6/STAT3 signaling. Tissue microarray analysis revealed co-expression correlations between individual pairs of proteins of the stromal MAOA-induced Twist1/IL-6/STAT3 pathway in clinical specimens. Downstream of stromal MAOA, STAT3 also promotes cell stemness and transcriptionally activates expression of cancer stem cell marker CD44 in PC cells. MAOA inhibitor treatment effectively suppressed prostate tumor growth in mice in a stroma-specific targeted manner. Collectively, these findings characterize the contribution of MAOA to stromal activation in PC pathogenesis and provide a rationale for targeting MAOA in stromal cells to treat PC.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32066880     DOI: 10.1038/s41388-020-1217-4

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  52 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

Review 2.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

Review 3.  The reactive stroma microenvironment and prostate cancer progression.

Authors:  David A Barron; David R Rowley
Journal:  Endocr Relat Cancer       Date:  2012-10-30       Impact factor: 5.678

4.  [Eutopic and ectopic hormone formation in the APUD endocrine cell system].

Authors:  J Blahos; J Jensovský
Journal:  Vnitr Lek       Date:  1985-11

Review 5.  Inflammation in prostate carcinogenesis.

Authors:  Angelo M De Marzo; Elizabeth A Platz; Siobhan Sutcliffe; Jianfeng Xu; Henrik Grönberg; Charles G Drake; Yasutomo Nakai; William B Isaacs; William G Nelson
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

6.  IL-6/IL-6R as a potential key signaling pathway in prostate cancer development.

Authors:  Andreia Azevedo; Virginia Cunha; Ana Luisa Teixeira; Rui Medeiros
Journal:  World J Clin Oncol       Date:  2011-12-10

7.  Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner.

Authors:  Neta Erez; Morgan Truitt; Peter Olson; Sarah Tuttleton Arron; Douglas Hanahan
Journal:  Cancer Cell       Date:  2010-02-04       Impact factor: 31.743

8.  Inflammation and cancer: IL-6 and STAT3 complete the link.

Authors:  Jacqueline Bromberg; Timothy C Wang
Journal:  Cancer Cell       Date:  2009-02-03       Impact factor: 31.743

9.  Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis.

Authors:  Maria T Diaz-Meco; Jorge Moscat; Tania Valencia; Ji Young Kim; Shadi Abu-Baker; Jorge Moscat-Pardos; Christopher S Ahn; Miguel Reina-Campos; Angeles Duran; Elias A Castilla; Christian M Metallo
Journal:  Cancer Cell       Date:  2014-07-04       Impact factor: 31.743

10.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

View more
  6 in total

Review 1.  Advances in neuroendocrine prostate cancer research: From model construction to molecular network analyses.

Authors:  Xue Shui; Rong Xu; Caiqin Zhang; Han Meng; Jumei Zhao; Changhong Shi
Journal:  Lab Invest       Date:  2021-12-22       Impact factor: 5.662

2.  Identification of Differentially Expressed circRNAs, miRNAs, and Genes in Patients Associated with Cartilaginous Endplate Degeneration.

Authors:  Haiwei Xu; Yongjin Li; Jianhua Li; Zhenxin Huo; Guowang Li; Lilong Du; Lijun Tian; Baoshan Xu
Journal:  Biomed Res Int       Date:  2021-05-18       Impact factor: 3.411

3.  Silencing of ISLR inhibits tumour progression and glycolysis by inactivating the IL‑6/JAK/STAT3 pathway in non‑small cell lung cancer.

Authors:  Peng Zhang; Zhen Li; Guangming Yang
Journal:  Int J Mol Med       Date:  2021-10-29       Impact factor: 4.101

4.  Integrated Metabolomics and Network Pharmacology Study on the Mechanism of Kangfuxiaoyan Suppository for Treating Chronic Pelvic Inflammatory Disease.

Authors:  Zhengyi Zhang; Ziye Xie; Shujing Lv; Yulian Shi; Chuanjia Zhai; Xuejiao Li; Bin Qiao; Xiaoyan Gao
Journal:  Front Pharmacol       Date:  2022-02-04       Impact factor: 5.810

5.  Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer.

Authors:  Martin Puhr; Andrea Eigentler; Florian Handle; Hubert Hackl; Christian Ploner; Isabel Heidegger; Georg Schaefer; Maximilian P Brandt; Julia Hoefer; Gabri Van der Pluijm; Helmut Klocker
Journal:  Oncogene       Date:  2021-04-01       Impact factor: 9.867

6.  Aberrant tryptophan metabolism in stromal cells is associated with mesenteric fibrosis in small intestinal neuroendocrine tumors.

Authors:  Anela Blažević; Anand M Iyer; Marie-Louise F van Velthuysen; Johannes Hofland; Peter M van Koestveld; Gaston J H Franssen; Richard A Feelders; Marina Zajec; Theo M Luider; Wouter W de Herder; Leo J Hofland
Journal:  Endocr Connect       Date:  2022-04-29       Impact factor: 3.221

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.